Summary:
Psychiatric Care and Research Center is conducting an open-label, flexible-dose, long-term study to evaluate the safety and tolerability of Brexpiprazole as add-on therapy in elderly patients with Major Depression who are not responding to their current antidepressant treatment.
Qualified Participants Must:
• Be 65 years or older
•
Have a major Depression lasting at least 8 weeks
•
Have an inadequate response to at least one antidepressant treatment in the current depressive episode
•
Currently be treated with an antidepressant
•
Not have an unstable medical illness
Qualified Participants May Receive:
Compensation for time and travel may be possible.